Table 1 Characteristics of subjects under analysis with duration and number of treatments
From: Effect of high-dose intravenous vitamin C on inflammation in cancer patients
Type of cancer | Age | Sex | CRP before | CRP after | Days of treatment | Number of treatments | Conventional treatment |
|---|---|---|---|---|---|---|---|
Anorectal adenocarcinoma, grade 3, invasive | 60 | F | 19.6 | 1.9 | 663 | 4 | low anterior resection, colorectostomy |
Biliary cancer, cholangiocarcinoma S-III(IV) | 77 | M | 19.58 | 143.76 | 68 | 33 | No records (NR) |
Bladder - transitional cell carcinoma x 2, grade 3 | 66 | M | 57.5 | 11 | 76 | 7 | operations, post treatment cycles |
Bladder, grade 3 | 65 | M | 6.09 | 0.94 | 167 | 7 | 2 times surgery |
Breast | 71 | M | 6.2 | 3.1 | 179 | 2 | mastectomy, Tomoxifen |
Breast | 57 | F | 19.4 | 0.4 | 512 | 47 | NR |
Breast | 82 | F | 22 | 8.9 | 132 | 2 | radiation, 36 treatments |
Breast | 66 | F | 12 | 2.25 | 193 | 3 | Lamoxifin - 1.5 year |
Breast | 89 | F | 4.1 | 8.5 | 454 | 19 | NR |
Breast, ductal carcinoma in situ, high nuclear grade | 67 | F | 21.1 | 5.5 | 555 | 12 | no surgery |
Breast carcinoma in situ, Basal cell carcinoma, Lymphoma | 71 | F | 133.2 | 2.3 | 682 | Â | surgery, mastectomy, chemotherapy |
Breast, category 5 | 78 | F | 8.6 | 13.1 | 379 | 20 | NR |
Breast, poorly differentiated duct cell carcinoma grade 4, Pancreas, malignant stage III, nonresectable | 78 | F | 3.7 | 8.9 | 233 | 4 | no radiation or chemotherapy, mastectomy |
Breast, infiltrating tubular carcinoma | 77 | F | 2.7 | 7.9 | 232 | 3 | no radiation, chemotherapy or mastectomy |
Breast, stage 1, T1 OMO, grade 2 | 53 | F | 12 | 3.8 | 44 | 11 | lumpectomy |
Breast, Stage IIA; Nottingham grade 2 | 69 | F | 9.3 | 3 | 121 | 20 | breast lumpectomy; partial mastectomy; excision (L) breast; |
Colon, stage IV, liver cancer | 64 | M | 44 | 3.4 | 232 | 12 | surgery, chemotherapy, hepatic resection |
Gastric cancer | 70 | M | 1.6 | 59.8 | 159 | 15 | NR |
Large B cell lymphoma | 25 | F | 10.5 | 0.3 | 82 | 18 | NR |
Lung | 65 | M | 216 | 35.9 | 174 | 27 | NR |
Lung - squamous cell, grade 2 | 80 | M | 9 | 6.7 | 82 | 20 | surgery, no chemotherapy |
Lung, renal | 82 | F | 19.2 | 59 | 167 | 37 | NR |
Lymphoma | 53 | F | 10.8 | 5.2 | 110 | 5 | Immune therapy 4 treatments/week every 6 months, Rutuxin |
Pancreas | 85 | M | 3.8 | 54.5 | 42 | 11 | NR |
Pancreas, breast | 71 | F | 10.1 | 0.4 | 119 | 44 | NR |
Pancreas, liver and bone metastasis | 89 | M | 2 | 25 | 423 | Â | cholecystojejunostomy and gastrojejunostomy |
Pros, Gleason score 6-8 | 82 | M | 3.9 | 8.8 | 279 | 8 | no surgery or hormonal therapy |
Prostate | 77 | M | 26.2 | 0.4 | 261 | 16 | NR |
Prostate | 80 | M | 153.3 | 148.4 | 11 | 5 | NR |
Prostate | 93 | M | 29.2 | 2.1 | 136 | 20 | NR |
Prostate, colon cancer | 89 | M | 43.4 | 31.5 | 113 | 5 | chemotherapy, colonectomy |
Prostate, Gleason score 2.5, malignant skin melanoma | 72 | M | 6 | 0.9 | 140 | 8 | NR |
Prostate, Gleason score 6 | 53 | M | 8.4 | 1.9 | 38 | 4 | surgery |
Prostate, Gleason score 6, squamous cell melanoma, bone cancer | 78 | M | 35.5 | 1.3 | 23 | 4 | radical prosectomy |
Prostate, Gleason score 6, stage T2A | 72 | M | 22.1 | 3.66 | 400 | Â | surgery |
Prostate, Gleason score 7 | 78 | M | 16.7 | 4.8 | 401 | 4 | radiation and hormonal therapy |
Prostate, pancreas | 74 | M | 14.9 | 40.7 | 89 | 24 | NR |
Prostate, pancreas | 86 | M | 500 | 54.3 | 542 | 102 | NR |
Prostate, stage I | 65 | M | 2.53 | 8.59 | 82 | 1 | prostatectomy |
Prostate, Gleason score 4, increased to 6–9 during 2 years | 81 | M | 5 | 0.6 | 1449 | 3 | NR |
Prostate, Esophageal cancer | 84 | M | 15.3 | 3.1 | 37 | 6 | removal of esophagus |
Prostate, metastatic adenocarcinoma, Gleason score 4 + 4 = 8 | 74 | M | 25 | 0.7 | 791 | 7 | radical prostatectomy |
Rectal adenocarcinoma, invasive through muscle layer | 71 | M | 2.2 | 7.2 | 137 | 2 | chemotherapy radiation |
Renal, Basal cell carcinoma | 82 | M | 30.5 | 19.5 | 48 | 10 | operation, 33 treatments by radiation |
Skin, B-cell Lymphoma, Lung | 83 | M | 8.9 | 1.5 | 754 | 36 | surgery, 40 radiations |